Conference abstract

Capsaicin and diabetic neuropathy; a randomized double blind placebo-controlled clinical trial

Pan African Medical Journal - Conference Proceedings. 2021:11(14).20 Jan 2021.
doi: 10.11604/pamj-cp.2021.11.14.911
Archived on: 20 Jan 2021
Contact the corresponding author
Keywords: Diabetes, neuropathy, pain, capsaicin

Capsaicin and diabetic neuropathy; a randomized double blind placebo-controlled clinical trial

Batakeh Ba Agoons, Mesmin Dehayem,Faustin Yepnjio, Dayawa Da Agoons, Martine Etoa Etoga, Eugène Sobngwi, Jean-Claude Mbanya

1National Obesity Center, Endocrine and Metabolic Diseases Unit, Central Hospital, Yaoundé, Cameroon, 2Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 3Department of surgery, Johns Hopkins university school of Medicine, USA, 4Biotechnology center, Yaoundé, Cameroon

&Corresponding author

Introduction: painful peripheral neuropathy is a common complication of diabetes and its management is difficult. Neurotropic drugs, which are the drugs of choice, have moderate efficacy due to high first pass metabolism. Topical Capsaicin, derived from the capsicum plant, is effective in relieving the pain of diabetic peripheral neuropathy in Caucasians. Due to an intercultural bias in pain treatment response, we evaluated the efficacy of Capsaicin on painful diabetic neuropathy in sub-Saharan subjects. METHODS: we conducted a randomized, double-blind clinical trial in patients with type 2 diabetes with painful diabetic polyneuropathy. They were assigned to 2 groups; Capsaicin (n = 11) vs placebo (n = 11), administered topically three times daily for 08 weeks. Pain intensity was noted in both groups, using a visual analogue scale, at intervals of 2 weeks. RESULTS: twenty-two patients, aged 55 ± 7 years, with an average pain intensity of 6.3 units in the Capsaicin group and 5.8 units in the placebo group were included. At inclusion, there was no significant difference in the 2 groups (p = 0.52). After 02 weeks, the mean value of pain intensity was 3.3±1.1 vs 5.4±1.9 (p = 0.004), at week 4, 3.2 ± 1.1 vs 4.7 ± 1.5 (p = 0,015), at week 6, 3.5 ± 1.6 vs 5.3±1.6 (p = 0.018) and at week 8, 6.6 ± 1.3 vs 5.4 ± 1.2 (p = 0.55) for capsaicin and placebo respectively. The main side effect in the capsaicin group was burning sensations in the application zones. Conclusion: Capsaicin significantly reduced neuropathic pain in the intervention group; however the pain worsened at week 8. It therefore has a transient positive effect on neuropathic pain in sub-Saharan subjects.